List of Cosela drug patents
Cosela is owned by G1 Therap.
Cosela contains Trilaciclib Dihydrochloride.
Cosela has a total of 10 drug patents out of which 0 drug patents have expired.
Cosela was authorised for market use on 12 February, 2021.
Cosela is available in powder;intravenous dosage forms.
Cosela can be used as a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer.
Drug patent challenges can be filed against Cosela from February, 2025.
The generics of Cosela are possible to be released after 14 March, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8598186 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US9957276 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US10189849 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US8598197 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10189850 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US10927120 | G1 THERAP | CDK inhibitors |
Oct, 2031
(8 years from now) | |
| US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic